Sinocelltech Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Beijing China (2002)

Organization Overview

First Clinical Trial
2012
NCT02206308
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SCT | Sinocelltech Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Colorectal Neoplasms (Phase 2)

Coronavirus Infections (Phase 1)

Esophageal Squamous Cell Carcinoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hemophilia A (Phase 4)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Macular Degeneration (Phase 2)

Neoplasms (Phase 2)

Psoriasis (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 29